1. Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Issue 11 (November 2018) Authors: Halpern, Anna; Othus, Megan; Huebner, Emily; Scott, Bart; Becker, Pamela; Percival, Mary-Elizabeth; Hendrie, Paul; Gardner, Kelda; Chen, Tara; Buckley, Sarah; Orlowski, Kaysey; Anwar, Asma; Appelbaum, Frederick; Erba, Harry; Estey, Elihu; Walter, Roland Journal: Leukemia Issue: Volume 32:Issue 11(2018) Page Start: 2352 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗